← Back to Screener
Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL)
Price$3.72
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)170.59%
Price vs S&P 500 (4W)-8.37%
VGM Score86.71
Market Capitalization$281.19M
All Metrics
Book Value / Share (Quarterly)$2.57
P/TBV (Annual)10.47x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.77
Price vs S&P 500 (YTD)181.21%
EPS (TTM)$-1.91
10-Day Avg Trading Volume0.81M
EPS Excl Extra (TTM)$-1.91
EPS (Annual)$-1.91
ROI (Annual)-63.39%
Cash / Share (Quarterly)$2.98
ROA (Last FY)-47.43%
EBITD / Share (TTM)$-2.12
ROE (5Y Avg)-55.52%
Cash Flow / Share (Annual)$-1.81
P/B Ratio1.54x
P/B Ratio (Quarterly)0.91x
Net Income / Employee (Annual)$-1,293,000
ROA (TTM)-40.55%
EPS Incl Extra (Annual)$-1.91
Current Ratio (Annual)6.93x
Quick Ratio (Quarterly)6.01x
3-Month Avg Trading Volume1.59M
52-Week Price Return208.59%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.00
P/S Ratio (Annual)4.17x
Asset Turnover (Annual)0.16x
52-Week High$6.95
EPS Excl Extra (Annual)$-1.91
CapEx CAGR (5Y)-8.79%
26-Week Price Return184.17%
Quick Ratio (Annual)6.73x
13-Week Price Return58.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.19x
Enterprise Value$249.26M
Book Value / Share Growth (5Y)-16.10%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-245.74%
Cash / Share (Annual)$3.56
3-Month Return Std Dev185.62%
Net Income / Employee (TTM)$-1,293,000
ROE (Last FY)-63.39%
EPS Basic Excl Extra (Annual)$-1.91
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.91
Receivables Turnover (Annual)0.00x
ROI (TTM)-52.77%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.00
Price vs S&P 500 (52W)180.44%
Year-to-Date Return192.59%
5-Day Price Return-1.74%
EPS Normalized (Annual)$-1.91
ROA (5Y Avg)-43.55%
Net Profit Margin (Annual)-245.96%
Month-to-Date Return-1.25%
Cash Flow / Share (TTM)$-3.33
EBITD / Share (Annual)$-2.12
Operating Margin (Annual)-283.57%
ROI (5Y Avg)-55.52%
EPS Basic Excl Extra (TTM)$-1.91
P/TBV (Quarterly)10.47x
P/B Ratio (Annual)0.45x
Book Value / Share (Annual)$3.13
Price vs S&P 500 (13W)47.34%
Beta2.01x
Revenue / Share (TTM)$0.00
ROE (TTM)-52.77%
52-Week Low$1.13
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.50est. -0.49
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.87
3.87
3.87
3.87
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZNTLZentalis Pharmaceuticals, Inc. Common Stock | — | — | A | $3.72 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, a potentially first-in-class WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. The company's lead program targets a specific patient population with limited existing treatment options and represents a focused therapeutic approach to an underserved indication.